Grano v. Sodexo, Inc.

District Court, S.D. California·Decided December 3, 2020·No. 3:18-cv-01818·Unknown

Opinion

VINCENT GRANO, an individual, Case No.: 18-CV-1818 TWR (BLM)

Plaintiff, ORDER (1) GRANTING THE v. AMENDING PLAINTIFFS’ MOTION FOR LEAVE TO FILE AMENDED SODEXO MANAGEMENT, INC., a New COMPLAINTS, (2) DENYING AS York Corporation; and CARGILL MEAT MOOT DEFENDANT US FOODS’ SOLUTIONS CORP., a Delaware MOTIONS TO DISMISS, AND Corporation, (3) GRANTING IN PART AND Defendants. DENYING IN PART PLAINTIFFS’ MOTION TO STRIKE AND ALL RELATED CASES (ECF Nos. 184, 187, 191, 194–200, 238)

Presently before the Court are several fully briefed motions in these eight consolidated actions:1 Plaintiffs Vincent Grano, Tristan Abbott, Bailey Anderson, Michael 1 On March 9, 2020, the Honorable Gonzalo P. Curiel consolidated the following cases: Abbott v. Sodexo Mgmt., Inc., No. 19-CV-1917 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); Miller v. Sodexo Mgmt., Inc., No. 19-CV-1909 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); Lader v. Sodexo Mgmt., Inc., No. 19-CV- 1908 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); Evers v. Sodexo Mgmt., Inc., No. 19-CV-1907 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); Browning v. Sodexo Mgmt., Inc., No. 19-CV-1905 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); Baker v. Sodexo Mgmt., Inc., No. 19-CV-1904 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); Anderson v. Sodexo Mgmt., Inc., No. 19-CV-1903 TWR (BLM) (S.D. Cal. filed Oct. 2, 2019); and Grano v. Sodexo, Inc., No. 18-CV-1818 TWR (BLM) (S.D. Cal. filed Aug. 3, 2018). (See Baker, Hunter Browning, Chase Evers, Conner Lader, and Frank Miller’s Motion to Strike Defendant Sodexo Management, Inc.’s Affirmative Defenses (“Mot. to Strike,” ECF No. 187); Amending Plaintiffs Abbott, Anderson, Baker, Browning, Evers, Lader, and Miller’s Motion for Leave Under FRCP 15(a)(2) to File Amended Complaints (“Mot. to Amend,” ECF No. 191); and Defendant US Foods’ Motions to Dismiss Plaintiffs Miller’s, Evers’, Lader’s, Browning’s, Anderson’s, Baker’s, and Abbott’s Second Amended Complaints (ECF Nos. 194–200, respectively, and the “Motions to Dismiss,” collectively). The Court held a hearing on November 20, 2020. (See ECF No. 247.) Having carefully considered Sodexo’s Answer to Plaintiff Grano’s Third Amended Complaint (ECF No. 184 (“Ans.”)), the Amending Plaintiffs’ Proposed Third Amended Complaints (ECF Nos. 191-3–9), the Parties’ arguments, and the law, the Court GRANTS the Amending Plaintiffs’ Motion to Amend, DENIES AS MOOT US Foods’ Motions to Dismiss, and GRANTS IN PART AND DENIES IN PART Plaintiffs’ Motion to Strike, as follows. I. Escherichia Coli Escherichia coli is a family of bacteria, most members of which do not cause human disease. (ECF No. 191-3 (“Proposed Abbott Compl.”) ¶ 43.2) The E. coli O157:H7 (or “STEC”) strain, however, can cause bloody diarrhea in humans and has a reputation as a significant health hazard. (Id.) E. coli O157:H7 is notable for its extremely low infectious dose, with as few as fifty bacteria capable of causing illness in a child. (Id. ¶ 44.) Approximately two to four days (and up to ten days) after ingestion, (id. ¶ 46), the bacteria attach to the inside surface of the large intestine, where they initiate an inflammatory reaction resulting in vomiting, diarrhea that can be bloody, and abdominal cramps. (Id. ¶¶ 45–46.) E. coli infections range from mild to life-threatening. (See id. ¶ 47.)

2 Although each of the Amending Plaintiffs has filed his own Proposed Third Amended Complaint, the allegations are substantially similar. (See ECF Nos. 191-3–9.) The Court therefore cites to Tristan Although most cases are mild and resolve within about a week without long-term effects, (id.), approximately ten percent of those infected develop a severe, potentially life- threatening complication called hemolytic uremic syndrome (“HUS”). (See id. ¶ 48.) HUS results in the destruction of red blood cells and platelets in the blood, which can result in clots that occlude the filtering units of the kidneys, leading to acute renal failure. (See id. ¶ 48.) Because antibiotics do not aid in combating E. coli infections, therapy is supportive. (See id. ¶ 47.) There is no known therapy to halt the progression of HUS, which has a mortality rate of approximately five percent. (Id. ¶ 49.) II. October 2017 STEC Outbreak at Camp Pendleton In October 2017, an outbreak of Shiga toxin-producing E. coli O157:H7 and O26 at United States Marine Corps Base Camp Pendleton (Edson Range) and the Marine Corp Recruit Depot sickened at least 244 Marine Corps recruits, including Plaintiffs. (See Proposed Abbott Compl. ¶¶ 8, 10.) Fifteen of those recruits developed HUS. (Id. ¶ 9.) By November 2017, all eight Plaintiffs to these consolidated actions had been hospitalized. (See ECF No. 202 (“US Foods Opp’n”) at 8; see also, e.g., Proposed Abbott Compl. ¶¶ 52–54.) Investigators from multiple public health agencies, including the Centers for Disease Control (“CDC”), conducted studies into the circumstances of the outbreak. (Proposed Abbott Compl. ¶ 12.) The investigators inspected the recruits’ sleep quarters, bathroom facilities, and the cafeterias, (see id.), and interviewed forty-three STEC patients and 135 healthy controls and other personnel. (Id. ¶ 13.) The CDC issued its report (the “CDC Report”) on January 23, 2018.3 (See id. ¶ 15.) The CDC Report revealed a statistically significant association between illness and the

Free access — add to your briefcase to read the full text and ask questions with AI

Grano v. Sodexo, Inc., (S.D. Cal. 2020).

Grano v. Sodexo, Inc. (Grano v. Sodexo, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Boyle v. United Technologies Corp.
487 U.S. 500 (Supreme Court, 1988)
Fogerty v. Fantasy, Inc.
510 U.S. 517 (Supreme Court, 1994)
United States v. Berry
618 F.3d 13 (D.C. Circuit, 2010)
United States v. Hiram Webb
655 F.2d 977 (Ninth Circuit, 1981)
Fantasy, Inc. v. Fogerty
984 F.2d 1524 (Ninth Circuit, 1993)
Norgart v. Upjohn Co.
981 P.2d 79 (California Supreme Court, 1999)
Bernson v. Browning-Ferris Industries of California, Inc.
873 P.2d 613 (California Supreme Court, 1994)
Neel v. Magana, Olney, Levy, Cathcart & Gelfand
491 P.2d 421 (California Supreme Court, 1971)
Kassatly v. Yazbeck
734 F. Supp. 13 (District of Columbia, 1990)
Colaprico v. Sun Microsystems, Inc.
758 F. Supp. 1335 (N.D. California, 1991)
Frederick v. Calbio Pharmaceuticals
89 Cal. App. 3d 49 (California Court of Appeal, 1979)
Pereira v. Dow Chemical Co.
129 Cal. App. 3d 865 (California Court of Appeal, 1982)